This week, we discuss two studies in gastrointestinal cancers presented at this year's European Society for Medical Oncology Congress. First up, the NEOLAP trial assessed induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX followed by surgical exploration in patients with locally advanced pancreatic cancer. Next, we'll discuss the ClarIDHy study, which examined treatment with ivosidenib in patients with advanced cholangiocarcinoma and an IDH1 mutation. We'll hear...
Jul 10, 2023•22 min•Ep. 22
This week, we discuss two studies in genitourinary cancers presented at the ESMO Congress 2019. The CARD trial investigated treatment with cabazitaxel vs an androgen signaling–targeted inhibitor among patients with metastatic castration-resistant prostate cancer who had disease progression on docetaxel and the alternative androgen signaling–targeted inhibitor. The IMvigor130 trial focused on the efficacy and safety of atezolizumab as monotherapy or combined with platinum-based chemotherapy vs pl...
Jul 10, 2023•18 min•Ep. 21
This week, we'll be discussing selected breast cancer abstracts presented at the ESMO Congress 2019, including the MONALEESA-3 and MONARCH-2 studies of CDK4/6 inhibitors for advanced breast cancer; the BROCADE 3 trial of veliparib plus carboplatin and paclitaxel in some advanced BRCA -mutated breast cancers; and the KATE-2 study of atezolizumab and trastuzumab emtansine in HER2-positive breast cancer. Coverage of stories discussed this week on ascopost.com: ESMO 2019: BROCADE 3: Veliparib Plus C...
Jul 10, 2023•15 min•Ep. 20
This week, we'll be discussing research highlights in lung cancer presented at the ESMO Congress 2019, including the FLAURA trial of osimertinib in EGFR-mutated non–small cell lung cancer; the CheckMate 227 of nivolumab plus ipilimumab vs chemotherapy in non–small cell lung cancer with a PD-L1 expression of 1% or more; and the ASCEND-7 trial of ceritinib for ALK-positive non–small cell lung cancer that has spread to the brain. Coverage of stories discussed this week on ascopost.com: ESMO 2019: O...
Jul 10, 2023•20 min•Ep. 19
This week, we review two studies from a Presidential Symposium at ESMO focusing on the efficacy of PARP inhibitors in patients with newly diagnosed ovarian cancer. Coverage of stories discussed this week on ascopost.com: ESMO 2019: Studies Show PARP Inhibitors Improve Survival, Reduce Risk of Disease Recurrence or Death in Newly Diagnosed Ovarian Cancer "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we review two studies from a Presidential Symposium at ESMO foc...
Jul 10, 2023•17 min•Ep. 18
This week, we review a presentation on the benefit of daratumumab across populations with newly diagnosed multiple myeloma. We also talk about a study on racial disparities in colorectal cancer mortality. Lastly, we discuss the FDA's recent approval of apalutamide in metastatic castration-sensitive prostate cancer. Coverage of stories discussed this week on ascopost.com: Tailoring Upfront Daratumumab Treatment for Some Patients With Multiple Myeloma AACR Disparities: Mortality Rate for Colorecta...
Jul 10, 2023•17 min•Ep. 17
This week, we'll be going over news from the ASTRO Annual Meeting, including an analysis of the effect of long-term hormonal therapy on men with low PSA levels treated with early salvage radiotherapy after radical prostatectomy and an update on the landmark PACIFIC trial in non–small cell lung cancer. We also discuss the launch of Project Orbis, which led to a joint approval from the FDA, the Australian Therapeutic Goods Administration, and Health Canada for lenvatinib in combination with pembro...
Jul 10, 2023•21 min•Ep. 16
This week, we'll be discussing findings presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer and the ASCO Quality Care Symposium, including a pooled analysis on 5-year overall survival rates in patients with previously treated non-small cell lung cancer receiving nivolumab vs docetaxel; the effect of out-of-pocket costs of tyrosine kinase inhibitors on survival in patients with lung cancer; and the relationship between participation in a...
Jul 10, 2023•18 min•Ep. 15
This week, we'll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we'll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we'll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students. Coverage of stories discussed this week on ascopost.com: Extended Follow-up of...
Jul 10, 2023•14 min•Ep. 14
This week, we review a pooled analysis of long-term survival rates in patients with previously treated non–small cell lung cancer treated with nivolumab. We then turn to the recently reported USPSTF recommendation on risk assessment, genetic counseling, and genetic testing for BRCA1 or BRCA2 mutations. Lastly, we discuss the recent FDA approval of entrectinib for NTRK -fusion cancers and ROS1 -positive NSCLC. Coverage of stories discussed this week on ascopost.com: Pooled Analysis of 4-Year Surv...
Jul 10, 2023•18 min•Ep. 13
This week, we review the U.S. Preventive Services Task Force (USPSTF) recommendation against screening for pancreatic cancer in adults with no symptoms. We also talk about the discovery of a germline mutation that has been newly associated with pancreatic cancer. Lastly, we discuss a U.S. Food and Drug Administration review which concluded a common Parkinson's disease drug does not contribute to the development of prostate cancer. Coverage of stories discussed this week on ascopost.com: USPSTF R...
Jul 10, 2023•16 min•Ep. 12
This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries. Coverage of stories discussed this week on ascopost.com: Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Pre...
Jul 10, 2023•17 min•Ep. 11
This week, we review a phase II trial of erdafitinib in urothelial carcinoma with an FGFR alteration. We also talk about a report from the World Health Organization on tobacco use worldwide. Then, we discuss two recent FDA approvals in prostate cancer and a rare joint tumor. Coverage of stories discussed this week on ascopost.com: Erdafitinib in FGFR -Altered Advanced Urothelial Carcinoma WHO Releases Report on the Global Tobacco Epidemic FDA Approves Darolutamide for Nonmetastatic Castration-Re...
Jul 10, 2023•15 min•Ep. 10
This week, we discuss an interim analysis of the MONALEESA-7 trial of the addition of ribociclib to endocrine therapy in pre- or perimenopausal women with advanced hormone receptor–positive, HER2-negative breast cancer. We also talk about a study that examined the relationship between the duration of chemotherapy and body mass index and the development of lymphedema in some patients with breast cancer. Lastly, we present three recent approvals and regulatory communications from the FDA. Coverage...
Jul 07, 2023•22 min•Ep. 9
This week, we discuss a study that found a disconnect between rates of colonoscopy and recent increases in colorectal cancer incidence in younger adults. In addition, Dr. Kimmie Ng, of Dana-Farber Cancer Institute, offers her insights on the rising rates of colorectal cancer in young adults. Then, we turn to a report on the relationship between androgen-deprivation therapy and rates of Alzheimer disease and dementia in elderly patients with prostate cancer. Coverage of stories discussed this wee...
Jul 07, 2023•18 min•Ep. 8
This week, we discuss long-term results from an extended analysis of the National Lung Screening Trial, and Dr. James Mulshine of Rush University offers his thoughts on these findings. We also review a report on radioactive iodine treatment for hyperthyroidism and long-term risk of death from solid cancers. Coverage of stories discussed this week on ascopost.com: Extended Follow-up From the National Lung Screening Trial Reported Does Radioactive Iodine Treatment for Hyperthyroidism Increase the ...
Jul 07, 2023•24 min•Ep. 7
We discuss two studies on colorectal cancer that were presented at the ESMO World Congress on Gastrointestinal Cancer. We also talk about a recently published study on the prevalence of pain among cancer survivors in the U.S. Coverage of stories discussed this week on ascopost.com: BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer REARRANGE Trial Examines Flexible Regorafenib Dosing in Refractory Metastatic Colorectal Cancer Chroni...
Jul 07, 2023•10 min•Ep. 6
In this episode, The ASCO Post's Editor-in-Chief Dr. James Armitage talks about the International Conference on Malignant Lymphoma (ICML), which he attended recently in Lugano, Switzerland; in particular, Dr. Armitage shares insight from a workshop on bridging liquid biopsy into the management of patients with lymphoma. He also discusses two studies from the plenary session looking at the impact of adding lenalidomide to R-CHOP in the management of diffuse large B-cell lymphoma. Later in the pod...
Jul 07, 2023•10 min•Ep. 5
In this episode, we discuss news from the Annual Congress of the European Hematology Association in multiple myeloma, catch up on a study presented at ASCO on gastric cancer, and review a recently published paper on prostate cancer development in World Trade Center first responders. Coverage of stories discussed this week on ascopost.com: EHA 2019: CASSIOPEIA Trial Examines Addition of Daratumumab to Standard Treatment Before and After ASCT in Multiple Myeloma Exposure to Specific Carcinogens an...
Jul 07, 2023•11 min•Ep. 4
In this episode, we discuss more news from the ASCO Annual Meeting, including findings from a study with relevance to surgical oncology, a summary of a study in HER2-positive breast cancer, and a third study on discrimination among hem/onc fellows. We also discuss two FDA approvals which took place in the last week. Coverage of stories discussed this week on ascopost.com: Discrimination, Gender Bias in Oncology Training and Professional Meetings FDA Approves New Trastuzumab Biosimilar FDA Expand...
Jul 07, 2023•16 min•Ep. 4
In this episode, we discuss more news from the ASCO Annual Meeting, sharing interviews with experts on studies in pancreatic, urothelial, and cervical cancers. We'll also tell you about a couple of new drug approvals announced this week by the FDA. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> In this episode, we discuss more news from the ASCO Annual Meeting, sharing interviews with experts on studies in pancreatic, urothelial, and cervical cancers. We'll also tell you a...
Jul 05, 2023•15 min•Ep. 2
This week, we're hearing from three experts on recent data focusing on the surgical management of breast cancer. All three speakers presented these findings at the 2023 Society of Surgical Oncology International Conference on Surgical Cancer Care, which took place at the end of March in Boston. To listen to more podcasts from ASCO, visit asco.org/podcasts .
May 05, 2023•18 min•Ep. 186
https://ascopost.com/podcasts/This week, we present reports on four important presentations made during the American Association for Cancer Research (AACR) Annual Meeting, focusing on novel inhibitory therapeutics; adjuvant immunotherapy for patients with hepatocellular carcinoma at high risk of recurrence; the effect of treatment protocols guided by precision medicine on survival for patients with relapsed or refractory cancer; and community engagement for clinical trial recruitment. To listen ...
Apr 28, 2023•18 min•Ep. 185
On this episode, we are sharing news presented during the American Association for Cancer Research (AACR) Annual Meeting, which was held earlier this month in Orlando. We feature three researchers discussing their findings in non–small cell lung cancer, early-stage breast cancer, and solid tumors harboring DNA damage response alterations. To listen to more podcasts from ASCO, visit asco.org/podcasts .
Apr 21, 2023•15 min•Ep. 184
The National Comprehensive Cancer Network, or NCCN, held its annual meeting recently in Orlando. On this week's episode of The ASCO Post podcast, we'll hear from two presenters who discussed quality of life issues in individuals with cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts .
Apr 14, 2023•11 min•Ep. 183
The National Comprehensive Cancer Network, or NCCN, held its annual meeting recently in Orlando. On this week's episode, we'll hear from two of the presenters who discussed NCCN Clinical Practice Guidelines Updates in chronic lymphocytic leukemia/small lymphocytic lymphoma and CNS cancers in adults. We'll also hear about a third presentation on the molecular landscape of metastatic colorectal cancer and its treatment. To listen to more podcasts from ASCO, visit asco.org/podcasts ....
Apr 07, 2023•17 min•Ep. 181
On this episode, we discuss two important studies presented over the past month at two oncology meetings, including the Society of Gynecologic Oncology Annual Meeting on Women's Cancer and the Miami Breast Cancer Conference. To listen to more podcasts from ASCO, visit asco.org/podcasts .
Mar 31, 2023•14 min•Ep. 180
On this episode, we discuss two studies that were presented at the Society of Surgical Oncology (SSO) 2023 International Conference on Surgical Cancer Care. First, we'll share results of the SWOGS1512 study of neoadjuvant pembrolizumab in patients with stage II to III desmoplastic melanoma. Then, we'll hear about a study which aimed to evaluate whether personalized ctDNA profiling could aid in identifying recurrence in patients with soft-tissue sarcomas. To listen to more podcasts from ASCO, vis...
Mar 24, 2023•10 min•Ep. 179
On this episode, we are recognizing colorectal cancer awareness month with two news items pertaining to gastrointestinal oncology reported over the past week. To listen to more podcasts from ASCO, visit asco.org/podcasts .
Mar 17, 2023•11 min•Ep. 178
On this week's episode, we're continuing our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium in San Francisco. Daniel Petrylak, MD, and Matt Galsky, MD, discuss two separate studies in urothelial carcinoma. Following this, in recognition of International Women's Day, we'll hear from Isabel Rubio, MD, PhD, President of the European Society of Surgical Oncology. Dr. Rubio shares some of the efforts being made by the Society to help encourage women to pursue a career in ...
Mar 10, 2023•17 min
